← Back to Search

Behavioral Intervention

Cognitive Behavioral Therapy for Nonepileptic Seizures

N/A
Recruiting
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
9-18 years old
Diagnosis of psychogenic non-epileptic seizures by a medical doctor using video-EEG
Must not have
Comorbid Epilepsy
Severe intellectual disability
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests ReACT therapy for children aged 11-18 with PNES. The therapy aims to help them feel more in control and less worried about their symptoms, potentially reducing seizure-like episodes.

Who is the study for?
This trial is for young people aged 9-18 with a diagnosis of psychogenic non-epileptic seizures (PNES) confirmed by video-EEG. They must experience at least four PNES per month and have a family member willing to participate. It's not suitable for those with severe mental illness, other nonepileptic events, participation in another therapy, severe intellectual disability, or comorbid epilepsy.
What is being tested?
The study tests Retraining and Control Therapy (ReACT), which aims to improve the sense of control and reduce catastrophic symptom expectations in children with PNES through twelve sessions. The effectiveness will be measured using tasks like holding a hand in cool water and questionnaires before treatment, after certain sessions, and up to one year later.
What are the potential side effects?
Since ReACT is a behavioral intervention focusing on changing thoughts and behaviors rather than medication, it may not have typical drug side effects. However, participants might experience discomfort during the cold pressor test or stress from confronting their condition.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 9 and 18 years old.
Select...
My seizures have been diagnosed as non-epileptic by a doctor using a special video test.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have epilepsy in addition to my primary condition.
Select...
I have a severe intellectual disability.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Magic and turbulence task
Pain Rating Scale
Pain catastrophizing scale for children- situation specific
+3 more
Secondary study objectives
Anxiety Sensitivity Index (ASI)
COVID-19 Functional Neurological Disorders (FND) Questionnaire
Child Self-Report Tic Questionnaire
+27 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Group I: ReACT for PNES- No Booster therapy sessionsExperimental Treatment1 Intervention
After completing the 12 ReACT treatment sessions, half of the participants will be randomized to not receive the 2 booster therapy sessions.
Group II: CPT- Pain sensitivity lotionExperimental Treatment1 Intervention
During the initial visit participant will do the cold pressor test twice to assess catastrophic symptom expectation. After completing the 1st CPT, participants will be randomized to receive a pain relief lotion or pain sensitivity lotion. Participants will then repeat the CPT with the lotion applied to their hand.
Group III: CPT- Pain relief lotionExperimental Treatment1 Intervention
During the initial visit participant will do the cold pressor test twice to assess catastrophic symptom expectations. After completing the 1st CPT, participants will be randomized to receive a pain relief lotion or pain sensitivity lotion. Participants will then repeat the CPT with the lotion applied to their hand.
Group IV: Healthy ControlActive Control1 Intervention
Healthy controls are matched to participants with PNES based on age (+ or - 1 year), gender, race and family income. Healthy controls and their parent come for 1 baseline laboratory visit and a follow up visit 13 weeks after the baseline visit. These visits will be identical to baseline and follow-up visits of children with PNES.
Group V: ReACT for PNES- Booster therapy sessionsActive Control1 Intervention
After completing the 12 therapy sessions, half of the participants will be randomized to receive 2 booster therapy sessions, 3 months and 9 months after the 12th ReACT treatment session.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ReACT
2016
N/A
~100

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Nonepileptic Seizures (PNES) that align with the principles of Retraining and Control Therapy (ReACT) involve cognitive-behavioral therapy (CBT) and other psychotherapeutic approaches. These treatments work by helping patients identify and modify dysfunctional thoughts and behaviors that contribute to their seizures. By improving the patient's sense of control and reducing catastrophic symptom expectations, these therapies can decrease the frequency and severity of PNES episodes. This is crucial for PNES patients as it addresses the underlying psychological factors, leading to better management of their condition and an improved quality of life.
The reduction of seizure-like behaviors through contingency management.Treatment approach in a child with hysterical seizures superimposed on partial complex seizures.Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,933 Previous Clinical Trials
2,741,410 Total Patients Enrolled
University of Alabama at BirminghamLead Sponsor
1,655 Previous Clinical Trials
2,444,045 Total Patients Enrolled

Media Library

ReACT (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05096273 — N/A
Nonepileptic Seizures Research Study Groups: Healthy Control, ReACT for PNES- Booster therapy sessions, ReACT for PNES- No Booster therapy sessions, CPT- Pain relief lotion, CPT- Pain sensitivity lotion
Nonepileptic Seizures Clinical Trial 2023: ReACT Highlights & Side Effects. Trial Name: NCT05096273 — N/A
ReACT (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05096273 — N/A
Nonepileptic Seizures Patient Testimony for trial: Trial Name: NCT05096273 — N/A
~21 spots leftby May 2026